News & Updates

Among patients who suffer from disorders of consciousness (DoC) after severe COVID-19, around 10 percent can achieve functional independence after 1 year, reports a study presented at the recently concluded 2022 Annual Meeting of the American Academy of Neurology (AAN 2022).

The experimental drug ecopipam helps minimize motor and phonic tics in children and adolescents with Tourette syndrome, in addition to being safe and well tolerated, according to the results of a phase 2b trial presented at the 2022 American Academy of Neurology’s Annual Meeting (AAN 2022).

Treatment with ofatumumab in the long term (approximately 3.5 years) among patients with relapsing multiple sclerosis (MS) is well-tolerated, with no new safety risks found, according to the results of ALITHIOS, presented at the 2022 Annual Meeting of the American Academy of Neurology.

The use of a combined biofeedback-virtual reality (VR) device as an add-on to standard medical care leads to a significant reduction in the need for acute medication in patients with chronic migraine, according to a study reported at the recently concluded 2022 Annual Meeting of the American Academy of Neurology (AAN 2022).

A recent systematic review has found studies that report cognitive decline among older patients with chronic pain and headache, but some papers have not seen such association.

An observational study from Singapore has shown that the incidence of cerebral venous thrombosis (CVT) following SARS-CoV-2 infection is greater than that following receipt of an mRNA-based SARS-CoV-2 vaccine.